LDK378 + AUY922
Phase 1Completed 0 watching 0 views this week💤 Quiet
33
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Anaplastic Lymphoma Kinase (ALK)
Conditions
Anaplastic Lymphoma Kinase (ALK), Non-small Cell Lung Cancer
Trial Timeline
Jun 1, 2013 → Jan 1, 2016
NCT ID
NCT01772797About LDK378 + AUY922
LDK378 + AUY922 is a phase 1 stage product being developed by Novartis for Anaplastic Lymphoma Kinase (ALK). The current trial status is completed. This product is registered under clinical trial identifier NCT01772797. Target conditions include Anaplastic Lymphoma Kinase (ALK), Non-small Cell Lung Cancer.
Hype Score Breakdown
Clinical
10
Activity
5
Company
10
Novelty
3
Community
2
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT01772797 | Phase 1 | Completed |
Competing Products
20 competing products in Anaplastic Lymphoma Kinase (ALK)
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| CS-7017 + Paclitaxel | Daiichi Sankyo | Phase 1/2 | 41 |
| efatutazone + paclitaxel | Daiichi Sankyo | Phase 2 | 52 |
| Lenvatinib 24 mg | Eisai | Phase 2 | 52 |
| Lenvatinib + Nivolumab | Ono Pharmaceutical | Phase 2 | 52 |
| durvalumab + tremelimumab | AstraZeneca | Phase 1 | 33 |
| Pembrolizumab | Merck | Phase 2 | 52 |
| ceritinib | Novartis | Pre-clinical | 23 |
| LDK378 | Novartis | Phase 1 | 33 |
| Ceritinib | Novartis | Phase 2 | 52 |
| Gemcitabine + ribociclib + sonidegib + trametinib + filgrastim | Novartis | Phase 1 | 33 |
| dabrafenib/trametinib | Novartis | Phase 2 | 52 |
| Trametinib + Paclitaxel | Novartis | Phase 1 | 33 |
| Alectinib + Crizotinib | Roche | Phase 3 | 77 |
| Sunitinib Malate | Pfizer | Phase 2 | 51 |
| Crizotinib (PF-02341066) | Pfizer | Phase 2 | 51 |
| Lorlatinib | Pfizer | Phase 2 | 51 |
| Crizotinib | Pfizer | Phase 1/2 | 40 |
| Cemiplimab + XL092 | Regeneron Pharmaceuticals | Phase 1 | 32 |
| Etirinotecan pegol | Nektar Therapeutics | Phase 2 | 47 |
| Bevacizumab | Novocure | Phase 2 | 47 |